0Q
0QIU.LSE Novo Nordisk A/S Class B
- Market cap
- DKK 19.9B
- P/E
- 0.4x
- P/B
- -
- ROE
- -
- Dividend yield
- 108.15%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2022.
Is 0QIU.LSE undervalued?
Graham numberThe Graham number of Novo Nordisk A/S Class B cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novo Nordisk A/S Class B fundamental analysis
No fundamental analysis for Novo Nordisk A/S Class B yet.
Novo Nordisk A/S Class B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novo Nordisk A/S Class B
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of hae…
Full company profileNovo Nordisk A/S Class B financial statements
2022 annualized: Fiscal year 2022 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2022, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novo Nordisk A/S Class B annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 112B | 112B | 122B | 127B | 141B | - |
| Gross Profit | 94.1B | 94.2B | 102B | 106B | 117B | - |
| Operating Income | 49.0B | 47.2B | 52.5B | 54.1B | 58.6B | - |
| Net Income | 38.1B | 38.6B | 39.0B | 42.1B | 47.8B | - |
| Balance Sheet | ||||||
| Total Assets | 102B | 111B | 126B | 145B | 195B | - |
| Total Liabilities | 52.5B | 58.9B | 68.0B | 81.6B | 124B | - |
| Shareholders' Equity | 49.8B | 51.8B | 57.6B | 63.3B | 70.7B | - |
| Cash & Short-term Investments | 18.9B | 15.6B | 15.0B | 12.1B | 16.4B | - |
| Total Debt | - | - | 3.01B | 2.90B | 13.0B | - |
| Cash Flow | ||||||
| Operating Cash Flow | 41.2B | 44.6B | 46.8B | 52.0B | 55.0B | 95.7B |
| Capital Expenditure | 8.65B | 9.64B | 8.93B | 5.83B | 6.34B | 9.58B |
| Ratios | ||||||
| ROE | 76.5% | 74.5% | 67.6% | 66.5% | 67.5% | - |
| ROA | 37.3% | 34.9% | 31.0% | 29.1% | 24.6% | - |
| Net Profit Margin | 34.1% | 34.5% | 31.9% | 33.2% | 33.9% | - |
| Debt to Equity | - | - | 0.05x | 0.05x | 0.18x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Novo Nordisk A/S Class B dividends
Novo Nordisk A/S Class B has not paid dividends in the last 5 fiscal years.
Last stock split: 5:1 on Jan 2, 2014.
Who owns Novo Nordisk A/S Class B
- Insiders 5.98%
- Institutions 41.95%
- Public & others 52.07%
- Shares outstanding 2.41B
- Free float 1.61B
Novo Nordisk A/S Class B company profile
- Company name
- Novo Nordisk A/S Class B
- Ticker
- 0QIU.LSE
- ISIN
- DK0062498333
- Exchange
- London Exchange
- Sector
- -
- Industry
- Commercial Services & Supplies
- Employees
- 59,337
- Fiscal year end
- December
- Address
- Novo Allé 1, Bagsvaerd, Denmark, 2880
- Phone
- 45 44 44 88 88
- Website
- novonordisk.com
About Novo Nordisk A/S Class B
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S Class B management
10- Mr. Lars Fruergaard JorgensenPres, CEO & Member of Management Board · born 1966
- Mr. Karsten Munk KnudsenExec. VP, CFO & Member of the Management Board · born 1971
- Mr. Henrik Ehlers WulffExec. VP, Head of Product Supply, Quality & IT and Member of the Management Board · born 1970
- Ms. Camilla SylvestExec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board · born 1972
- Dr. Martin Holst LangeExec. VP, Head of Devel. & Member of the Management Board · born 1970
- Ms. Monique CarterExec. VP, Head of People & Organisation and Member of Management Board · born 1973
- Dr. Marcus Schindler Ph.D.EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board · born 1966
- Mr. Maziar Mike DoustdarExec. VP, Head of International Operations & Member of the Management Board · born 1970
- Mr. Douglas J. LangaExec. VP, Head of North America Operations & Member of Management Board · born 1966
- Mr. Ludovic HelfgottExec. VP, Head of Rare Disease & Member of Management Board · born 1974